NCT02867566View on ClinicalTrials.gov

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

August 22, 2016

Primary Completion Date

September 5, 2019

Study Completion Date

December 26, 2019

Conditions
Diffuse, Large B-Cell, Lymphoma
Interventions
DRUG

IBI301 plus CHOP

Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.

DRUG

Rituximab plus CHOP

Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.

Trial Locations (1)

Unknown

Institute of Hematology; Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT02867566 - A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | Biotech Hunter | Biotech Hunter